Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer
Iwata T., Kimura S., Abufaraj M., Janisch F., Parizi M. K., Haitel A., Rink M., Rouprêt M., Fajkovic H., Seebacher V., Nyirady P., Karakiewicz P. I., Enikeev D. V., Rapoport L. M., Nasu Y., Shariat Sh.
Urologic Oncology
Vol.37, Issue10, P. 774-783
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.1016/j.urolonc.2019.05.019
Аннотация:
Objectives: To assess the role of the urokinase plasminogen activator (uPA) system as a prognostic biomarker in patients with nonmuscle invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB) with or without adjuvant intravesical therapy. Material and methods: We stained TURB tissue from 827 NMIBC patients with uPA, its receptor (uPAR) and its inhibitor (PAI-1). The status of these markers was categorized as normal vs. overexpressed using the cutoffs of 30[%] for uPA, 50[%] for uPAR, and 30[%] for PAI-1. Multivariable Cox regression analyses were performed to evaluate the prognostic value of these markers. Results: uPA was overexpressed in 37.7[%] of patients, uPAR in 44.7[%] and PAI-1 in 44.6[%]. Overexpression of these markers was associated with high tumor grade. Within a median follow-up was 60 months (interquartile range: 22–109), uPA (hazard ratio [HR]: 1.40; P = 0.006), uPAR (HR: 1.70; P < 0.001), PAI-1 (HR: 1.35; P = 0.014), and the combination of all 3 m
Ключевые слова:
Nonmuscle invasive bladder cancer; Progression; Recurrence; Urokinase plasminogen activator
antineoplastic agent; plasminogen activator inhibitor 1; urokinase; urokinase receptor; urokinase; adult; aged; Article; bright field microscopy; cancer adjuvant therapy; cancer grading; cancer prognosis; cancer staging; carcinogenesis; clinical decision making; clinical feature; controlled study; cystoscopy; diagnostic accuracy; female; follow up; human; human tissue; immunoreactivity; major clinical study; male; non muscle invasive bladder cancer; priority journal; progression free survival; recurrence free survival; retrospective study; transurethral resection; tumor volume; bladder tumor; clinical trial; genetics; immunohistochemistry; metabolism; middle aged; multicenter study; procedures; prognosis; Aged; Female; Humans; Immunohistochemistry; Male; Middle Aged; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms; Urokinase-Type Plasminogen Activator
Язык текста: Английский
ISSN: 1873-2496
Iwata T.
Kimura S.
Abufaraj M.
Janisch F.
Parizi M. K.
Haitel A.
Rink M.
Rouprêt M.
Fajkovic H.
Seebacher V.
Nyirady P.
Karakiewicz P. I.
Enikeev D. V. Dmitrij Viktorovich 1982-
Rapoport L. M. Leonid Moiseevich 1956-
Nasu Y.
Shariat Sh. Sharokh 1973-
Иwата Т.
Кимура С.
Абуфарай М.
Йанисч Ф.
Паризи М. К.
Хаител А.
Ринк М.
Роупрêт М.
Файковиc Х.
Сеебачер В.
Нyирадy П.
Каракиеwиcз П. И.
Еникеев Д. В. Дмитрий Викторович 1982-
Рапопорт Л. М. Леонид Моисеевич 1956-
Насу Y.
Шариат Ш. Шарох 1973-
Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer
Текст визуальный непосредственный
Urologic Oncology
Elsevier Science Publisher B.V.
Vol.37, Issue10 P. 774-783
2019
Статья
Nonmuscle invasive bladder cancer Progression Recurrence Urokinase plasminogen activator
antineoplastic agent plasminogen activator inhibitor 1 urokinase urokinase receptor urokinase adult aged Article bright field microscopy cancer adjuvant therapy cancer grading cancer prognosis cancer staging carcinogenesis clinical decision making clinical feature controlled study cystoscopy diagnostic accuracy female follow up human human tissue immunoreactivity major clinical study male non muscle invasive bladder cancer priority journal progression free survival recurrence free survival retrospective study transurethral resection tumor volume bladder tumor clinical trial genetics immunohistochemistry metabolism middle aged multicenter study procedures prognosis Aged Female Humans Immunohistochemistry Male Middle Aged Prognosis Retrospective Studies Urinary Bladder Neoplasms Urokinase-Type Plasminogen Activator
Objectives: To assess the role of the urokinase plasminogen activator (uPA) system as a prognostic biomarker in patients with nonmuscle invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB) with or without adjuvant intravesical therapy. Material and methods: We stained TURB tissue from 827 NMIBC patients with uPA, its receptor (uPAR) and its inhibitor (PAI-1). The status of these markers was categorized as normal vs. overexpressed using the cutoffs of 30[%] for uPA, 50[%] for uPAR, and 30[%] for PAI-1. Multivariable Cox regression analyses were performed to evaluate the prognostic value of these markers. Results: uPA was overexpressed in 37.7[%] of patients, uPAR in 44.7[%] and PAI-1 in 44.6[%]. Overexpression of these markers was associated with high tumor grade. Within a median follow-up was 60 months (interquartile range: 22–109), uPA (hazard ratio [HR]: 1.40; P = 0.006), uPAR (HR: 1.70; P < 0.001), PAI-1 (HR: 1.35; P = 0.014), and the combination of all 3 m